Roflumilast - Jiangsu Chia-tai Tianqing Pharmaceutical

Drug Profile

Roflumilast - Jiangsu Chia-tai Tianqing Pharmaceutical

Latest Information Update: 20 Apr 2016

Price : $50

At a glance

  • Originator Takeda
  • Developer Chia Tai Tianqing Pharmaceutical Group
  • Class Aminopyridines; Antiallergics; Antiasthmatics; Benzamides; Cyclopropanes; Small molecules
  • Mechanism of Action Type 4 cyclic nucleotide phosphodiesterase inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Phase II Chronic obstructive pulmonary disease

Most Recent Events

  • 15 Mar 2016 Biomarkers information updated
  • 01 Mar 2016 Phase-II clinical trials in Chronic obstructive pulmonary disease in China (PO) (NCT02671942)
  • 25 Jan 2016 Clinical trials in Chronic obstructive pulmonary disease in China (PO)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top